Cognition Therapeutics, Inc. (CGTX) earnings
CGTX earnings moved a median of -2.31% by the close. Quarterly and annual CGTX reports and results, each read against the price at its own news timestamp. Back to the CGTX overview →
23 measured CGTX earnings events.
Where these CGTX earnings landedvs 23 measured CGTX earnings reactions
| Middle 50% of CGTX earnings reactions | -8.58% to +0.16% |
|---|---|
| Median reaction (to close) | -2.31% |
| Measured reactions | 23 |
Point-in-time · zero look-ahead
Half of the 23 CGTX earnings events with a measured close landed between -8.58% and +0.16%; 26% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update | Press release | -4.17% | -11.75% | |
| Form 10-Q COGNITION THERAPEUTICS For: Sep 30 | SEC filing · Form 10-Q | -4.17% | -11.75% | |
| Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026 | Press release | +1.22% | +1.52% | |
| Form 10-Q COGNITION THERAPEUTICS For: Jun 30 | SEC filing · Form 10-Q | +1.82% | -1.82% | |
| Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update | Press release | +1.82% | -1.82% | |
| Form 10-Q COGNITION THERAPEUTICS For: Mar 31 | SEC filing · Form 10-Q | -0.43% | +3.42% | |
| Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update | Press release | -0.43% | +3.42% | |
| Form 10-K COGNITION THERAPEUTICS For: Dec 31 | SEC filing · Form 10-K | -1.79% | -3.57% | |
| Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs | Press release | +0.00% | -1.19% | |
| Form 10-Q COGNITION THERAPEUTICS For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -1.19% | |
| Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs | Press release | +3.76% | +11.68% | |
| Form 10-Q COGNITION THERAPEUTICS For: Jun 30 | SEC filing · Form 10-Q | +3.76% | +11.68% | |
| Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update | Press release | -4.10% | -8.58% | |
| Form 10-Q COGNITION THERAPEUTICS For: Mar 31 | SEC filing · Form 10-Q | -4.10% | -8.58% | |
| Form 10-K COGNITION THERAPEUTICS For: Dec 31 | SEC filing · Form 10-K | -4.25% | -9.21% | |
| Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update | Press release | -1.67% | -10.48% | |
| Form 10-Q COGNITION THERAPEUTICS For: Sep 30 | SEC filing · Form 10-Q | -1.67% | -10.48% | |
| Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update | Press release | +0.05% | -2.31% | |
| Form 10-Q COGNITION THERAPEUTICS For: Jun 30 | SEC filing · Form 10-Q | +0.05% | -2.31% | |
| Cognition Therapeutics to Report Second Quarter 2024 Financial Results | Press release | +1.71% | +11.20% | |
| Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update | Press release | -3.03% | -3.03% | |
| Form 10-Q COGNITION THERAPEUTICS For: Mar 31 | SEC filing · Form 10-Q | -3.03% | -3.03% | |
| Form 10-K COGNITION THERAPEUTICS For: Dec 31 | SEC filing · Form 10-K | +0.00% | -3.19% |
Keep exploring
More CGTX: analyst actions → · SEC filings → · CGTX overview →